A Study of Seladelpar in Patients with Primary Biliary Cholangitis (PBC) and Abnormal Liver Function
Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!
a study on Primary Biliary Cholangitis Cirrhosis Hepatic Impairment Liver Disease
- for people ages 18-80 (full criteria)
- at Sacramento, California and other locations
- study startedestimated completion
Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment, PBC, Primary Biliary Cholangitis (PBC), Liver Diseases, Cholangitis, Biliary Liver Cirrhosis, Seladelpar, Seladelpar 10 mg, Seladelpar 10 mg or less
- accepting new patients
- Start Date
- Completion Date
- CymaBay Therapeutics, Inc.
- Sign up for this study
- Phase 1 research study
- Study Type
- Expecting 24 study participants
- Last Updated